Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 12/20 | 0.58 |
| ▸ | OPRL1 | P41146 | 5/20 | 0.40 |
| ▸ | HTR1B | P28222 | 1/20 | 0.38 |
| ▸ | CX3CR1 | P49238 | 1/20 | 0.38 |
| ▸ | MMP13 | P45452 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | MYLK | Q15746 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL489576 | 0.85 | CXCR2 (0.75) | CXCR2OPRL1HTR1BCX3CR1MEN1 | |
| SCHEMBL490197 | 0.81 | CXCR2 (0.49) | CXCR2HTR1BCX3CR1MEN1TP53 | |
| SCHEMBL490039 | 0.80 | CXCR2 (0.65) | CXCR2OPRL1HTR1BCX3CR1MEN1 | |
| SCHEMBL1646509 | 0.76 | CXCR2 (0.72) | CXCR2OPRL1HTR1BCX3CR1 | |
| SCHEMBL490086 | 0.75 | MPO (0.48) | CXCR2HTR1BCX3CR1MEN1KMT2A | |
| SCHEMBL489780 | 0.74 | CXCR2 (0.75) | CXCR2 | |
| SCHEMBL490272 | 0.74 | CXCR2 (0.65) | CXCR2HTR1BCX3CR1 | |
| SCHEMBL489772 | 0.74 | CXCR2 (1.00) | CXCR2HTR1BCX3CR1 | |
| SCHEMBL489912 | 0.73 | CXCR2 (0.83) | CXCR2HTR1BCX3CR1 | |
| SCHEMBL489669 | 0.72 | CXCR2 (0.63) | CXCR2HTR1BCX3CR1CYP2D6KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1527051-B1 | PYRIMIDYL SULPHONE AMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2012-09-12 | — | — | EP | disclosed |
| US-8106063-B2 | Pyrimidyl sulphone amide derivatives as chemokine receptor modulators | ASTRAZENECA AB (SE) | 2012-01-31 | — | — | US | disclosed |
| US-20100063079-A1 | Pyrimidyl Sulphone Amide Derivatives as Chemokine Receptor Modulators | ASTRAZENECA AB (SE) | 2010-03-11 | — | — | US | disclosed |
| US-7582644-B2 | Pyrimidyl sulphone amide derivatives as chemokine receptor modulators | ASTRAZENECA AB (SE) | 2009-09-01 | — | — | US | disclosed |
| US-20060025432-A1 | Pyrimidyl sulphone amide derivatives as chemokine receptor modulators | ASTRAZENECA AB (SE) | 2006-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063079-A1 | Pyrimidyl Sulphone Amide Derivatives as Chemokine Receptor Modulators | ACKR3, GPR17, CCL11 | CXCR2 38/4885OPRL1 94/4885HTR1B 2017/4885 |
| US-20060025432-A1 | Pyrimidyl sulphone amide derivatives as chemokine receptor modulators | ACKR3, GPR17, CCL11 | CXCR2 38/4885OPRL1 94/4885HTR1B 2017/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.